

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|---------------|
| Application Number | 10/564,494 |
| Filing Date | June 27, 2007 |
| First Named Inventor | Cook |
| Group Art Unit | 4121 |
| Examiner Name | Shomer, Isaac |

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Document No. | Date | Name | Class | Subclass | Filing Date (if appropriate) |
|---------------------|----------|--------------|------------|------------------|-------|----------|------------------------------|
| | D1 | 3,664,963 | 5/23/1972 | Pasin | | | |
| | D2 | 3,780,195 | 12/18/1973 | Balassa | | | |
| | D3 | 3,790,905 | 2/5/1974 | Sato | | | |
| | D4 | 3,891,570 | 6/24/1975 | Fukushima | | | |
| | D5 | 4,183,681 | 1/15/1980 | Li | | | |
| | D6 | 4,299,501 | 11/10/1981 | Patil | | | |
| | D7 | 5,733,566 | 3/1/1998 | Lewis | | | |
| | D8 | 5,846,562 | 12/1/1998 | Yanai et al. | | | |
| | D9 | 6,140,040 | 10/1/2000 | Palm et al. | | | |
| | D10 | 6,194,006 | 2/1/2001 | Lyons et al. | | | |
| | D11 | 6,369,121 | 4/1/2002 | Catalfamo et al. | | | |
| | D12 | 6,379,704 | 4/1/2002 | Wright et al. | | | |
| | D13 | 2002-0025329 | 2/1/2002 | O'Hagan et al. | | | |
| | D14 | 2002-0028216 | 3/1/2002 | Donovan | | | |
| | D15 | 2006-0228414 | 1/11/2006 | Cook | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code | Date | Name | Translation Yes No |
|---------------------|----------|--|------------|-------------------------|-----------------------|
| | D16 | WO 2003/092585 | 11/13/2003 | PR Pharmaceuticals Inc. | |
| | D17 | WO 2005/003180 | 1/13/2005 | PR Pharmaceuticals Inc. | |
| | D18 | WO 2005/009356 | 2/3/2005 | Cook | |
| | D19 | WO 2005/009357 | 2/3/2005 | Cook | |

NON-PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|--|
| | D20 | Yanai <i>et al.</i> , "Optimal formulation of an angiogenesis inhibitor, TNP-470, for arterial injection determined by in vitro drug release and stability, and in vivo activity," International Journal of Pharmaceuticals 123:237-245 (1995) |
| | | |
| | | |
| | | |
| | | |

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.